BD (Becton, Dickinson and Company) is making progress toward its objective of of...
Medeor Therapeutics’ MDR-101 is a single-dose cell therapy designed to revolutio...
Kronos Bio, following promising outcomes in an initial evaluation of a phase 1/2...
In a surprising turn of events, AstraZeneca’s once-forgotten drug, zibotentan, h...
FDA advisers have expressed contentment with CRISPR Therapeutics and Vertex Phar...
C4 Therapeutics has made the decision to discontinue the development of one of i...
Over three years following the initial approval of a pharmaceutical by Deciphera...
GSK is crowing about a victory for its PD-1 inhibitor Jemperli after it was quic...
Merck KGaA is reaffirming its commitment to the burgeoning field of PARP inhibit...
Belgium is mulling over a temporary ban on the utilization of Novo Nordisk’s Oze...
FluMist, AstraZeneca’s nasal spray influenza vaccine, has been on the market for...
EnginZyme AB, a cutting-edge technology company specializing in enzymatic bioman...
Merck & Co. has chosen to streamline its portfolio of antibody-drug conjugates (...
Approximately a year ago, pharmaceutical company Roivant Sciences established a ...
Roche has made a significant $7 billion investment to challenge Merck & Co in th...
Merck & Co. is making a bold move in the world of pharmaceuticals, securing a si...
